Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Acute exercise enhances fear extinction through a mechanism involving central mTOR signaling.
Neurobiol Learn Mem. 2020 Dec;176:107328. doi: 10.1016/j.nlm.2020.107328. Epub 2020 Oct 17.
Neurobiol Learn Mem. 2020.
PMID: 33075479
Free PMC article.
Duration- and sex-dependent neural circuit control of voluntary physical activity.
Tanner MK, Davis JKP, Jaime J, Moya NA, Hohorst AA, Bonar K, Abrams KA, Jamil N, Han R, Hubert TJ, Brown N, Loetz EC, Greenwood BN.
Tanner MK, et al. Among authors: moya na.
Psychopharmacology (Berl). 2022 Nov;239(11):3697-3709. doi: 10.1007/s00213-022-06243-0. Epub 2022 Oct 4.
Psychopharmacology (Berl). 2022.
PMID: 36195731
Free PMC article.
Item in Clipboard
Pharmacological manipulations of the dorsomedial and dorsolateral striatum during fear extinction reveal opposing roles in fear renewal.
Tanner MK, Hohorst AA, Westerman JD, Mendoza CS, Han R, Moya NA, Jaime J, Alvarez LM, Dryden MQ, Balolia A, Abdul RA, Loetz EC, Greenwood BN.
Tanner MK, et al. Among authors: moya na.
Neurobiol Learn Mem. 2024 May 10:107937. doi: 10.1016/j.nlm.2024.107937. Online ahead of print.
Neurobiol Learn Mem. 2024.
PMID: 38735637
Item in Clipboard
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Moya NA, Yun S, Fleps SW, Martin MM, Nadel JA, Beutler LR, Zweifel LS, Parker JG.
Moya NA, et al.
Neuropsychopharmacology. 2023 Mar;48(4):690-699. doi: 10.1038/s41386-022-01492-1. Epub 2022 Nov 15.
Neuropsychopharmacology. 2023.
PMID: 36380221
Free PMC article.
Item in Clipboard
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group.
Ramasamy MN, et al.
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
Lancet. 2021.
PMID: 33220855
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite